PLASMA DERIVED MEDICINE MARKET ANALYSIS

Plasma Derived Medicine Market, By Product (Immunoglobulin, Coagulation factors, Albumin, and Others), By Application (Pelvic Inflammatory Disease (PID), Bleeding Disorders, Alpha-1 Antitrypsin Deficiency (AATD), Hereditary Angioedema (HAE), Chronic Inflammatory Demyelinating Polyneuropathy, Guillain-Barre Syndrome, Multifocal Motor Neuropathy, Liver Diseases, Primary Immune Thrombocytopenia, Infections, and Other Orphan Diseases), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Geography (North America, Latin America, Asia Pacific, Europe, Middle East, and Africa)

In June 2024, Takeda announced its plan to expand its Los Angeles plasma-derived therapies production facility with a US$ 230 million investment, marking one of its largest manufacturing expansions. This project, which will create over 125 new jobs, aims to enhance production capacity at Takeda's largest fractionation site globally. The expansion will support the growing demand for therapies for rare, chronic, and genetic diseases, ensuring a reliable supply of treatments and aligning with Takeda’s commitment to patient care, sustainable growth, and investment in key business areas.
In July 2020, Grifols, a leading producer of plasma-derived medicines, signed an agreement with GC Pharma to acquire a plasma fractionation facility in Montreal, along with 11 plasma collection centers in the U.S. and two purification facilities. This strategic acquisition enhanced Grifols' market revenue and reinforced its leading position in the industry.